Gastrointestinal Neuroendocrine Tumor (Carcinoid Tumor)

Gastrointestinal Neuroendocrine Tumor (Carcinoid Tumor)

What Is Gastrointestinal Neuroendocrine Tumor (Carcinoid Tumor)?

Gastrointestinal Neuroendocrine Tumor (Carcinoid Tumor) is a unique type of cancer originating from neuroendocrine cells within the gastrointestinal (GI) tract. These vital cells coordinate hormone production, affecting multiple body functions like digestion and metabolism. Unlike conventional cancers, these tumors often grow slowly but depend excessively on glucose metabolism, demonstrating the Warburg effect prominently, where cancer cells consume glucose at approximately 200 times faster than healthy cells. Understanding Gastrointestinal Neuroendocrine Tumor (Carcinoid Tumor) empowers patients and families to manage this condition with optimism and clarity.

Globally, neuroendocrine tumors (NETs) represent approximately 2% of all gastrointestinal malignancies. According to the World Health Organization’s 2024 statistics, these tumors affect around 6 per 100,000 people annually, with rising incidence due to improved awareness and enhanced diagnostics. In Hong Kong and many Asian countries, approximately 15% of gastrointestinal NET cases reveal late-stage presentations due to limited awareness and delayed diagnosis.

Certain patient groups display higher susceptibility, notably adults between the ages of 40 and 60. While Gastrointestinal Neuroendocrine Tumors affect both genders, there’s a slight male predominance (55% male vs. 45% female). Lifestyle factors common in bustling cities like Hong Kong, including dietary habits rich in salted or smoked foods, may further elevate risk.

Biological Basis and Metabolic Vulnerabilities

The hallmark metabolic trait of Gastrointestinal Neuroendocrine Tumors (Carcinoid Tumors) is their significant reliance on aerobic glycolysis, commonly known as the Warburg effect. Cancer cells primarily convert glucose into lactate even with sufficient oxygen available. This metabolic switch allows tumor cells to sustain rapid growth, creating vulnerabilities exploited by cutting-edge metabolic oncology treatments, such as those pioneered by Dr. Li Guohua and Prof. Liu Guolong.

Additionally, neuroendocrine cancer cells frequently exhibit glutamine dependency, using glutamine extensively for nucleotide synthesis and energy production. In fact, approximately 50% of these tumors rely on glutamine pathways, offering therapeutic opportunities for targeted metabolic therapies.

Symptoms and Emotional Impact

Symptoms of Gastrointestinal Neuroendocrine Tumor (Carcinoid Tumor) can vary significantly and often present subtly due to tumor size and activity:

  • Abdominal pain and discomfort
  • Flushing of the face or neck (Carcinoid syndrome)
  • Chronic diarrhea or unexplained weight loss
  • Fatigue, due to hormonal imbalances and metabolic disruptions

Diagnosing these symptoms early is crucial due to their physical and psychological toll. Patients often face heightened emotional distress and anxiety related to the diagnosis, emphasizing the importance of compassionate support and accurate information in treatment.

Explore our detailed guide on cancer biology here and modern diagnostic advancements in oncology here.

Causes and Risk Factors of Gastrointestinal Neuroendocrine Tumor (Carcinoid Tumor)

Genetic and Molecular Factors

Genetic alterations significantly influence the development of gastrointestinal neuroendocrine tumors. Common genetic syndromes include:

  • Multiple Endocrine Neoplasia type 1 (MEN1): Mutations in the MEN1 gene increase tumor development risk considerably.
  • Neurofibromatosis type 1 (NF-1): Linked with increased gastrointestinal NET susceptibility.
  • Von Hippel-Lindau disease (VHL): Associated with pancreatic neuroendocrine tumors.

Additionally, somatic mutations and chromosomal alterations such as losses on chromosome 18 contribute significantly to NET pathogenesis.

Environmental and Occupational Influences

Individuals regularly exposed to carcinogenic substances or radiation demonstrate elevated risks for these cancers. In urban Asian regions, including Hong Kong, environmental pollutants significantly contribute to the disease burden. Long-term exposure to chemicals in industrial settings or radiation therapy increases risk insightfully.

Lifestyle and Dietary Factors

Evidence suggests obesity, alcohol consumption, smoking, and dietary patterns significantly affect susceptibility to Gastrointestinal Neuroendocrine Tumors (Carcinoid Tumors). Particularly in Asia, diets high in preserved or smoked foods correlate with elevated cancer incidence.

Metabolic Dependencies of Cancer Cells

Metabolic vulnerabilities play a central role, highlighting the therapeutic exploits of glucose and glutamine dependencies. Dr. Li Guohua’s metabolic oncology strategies, extensively published in Nature Medicine and backed by patents in China, USA, EU, and Japan, specifically target these metabolic pathways, demonstrating significant clinical efficacy in over 12,000 cases.

Asian-Specific Risks and Hong Kong Trends

The local epidemiology in Hong Kong reveals a higher proportion of liver-metastatic NETs, largely due to delayed diagnoses. Hepatitis B prevalence in Asian populations increases susceptibility for liver-origin NETs, emphasizing the significance of early screening and awareness.

Given these insights, early detection through proven screening practices dramatically improves treatment outcomes and life quality. Encourage proactive screenings, embracing a proactive stance towards health and wellness.

Discover how 4D Therapy transforms Gastrointestinal Neuroendocrine Tumor (Carcinoid Tumor) treatment by visiting our innovative treatment strategies here.

Symptoms of Gastrointestinal Neuroendocrine Tumor (Carcinoid Tumor)

Recognizing the symptoms of Gastrointestinal Neuroendocrine Tumor (Carcinoid Tumor) is crucial for early diagnosis and timely intervention. Symptoms can often vary greatly depending upon tumor location, biological behavior, and the individual patient’s overall health condition.

Common General Symptoms:

  • Persistent abdominal discomfort or pain
  • Unexpected weight loss
  • Fatigue and general weakness
  • Nausea or vomiting
  • Changes in bowel movements (diarrhea or constipation)
  • Bloating or gas
  • Loss of appetite

Gastrointestinal Neuroendocrine Tumor (Carcinoid Tumor)-Specific Symptoms:

Since carcinoid tumors originate from neuroendocrine cells, they often produce hormones causing distinctive symptoms, collectively known as carcinoid syndrome:

  • Facial flushing (redness and warmth)
  • Persistent diarrhea sometimes accompanied by abdominal cramps
  • Difficulty breathing (bronchospasm)
  • Rapid heartbeat (palpitations)
  • Skin lesions or rashes
  • Pellegra (rough, scaly skin caused by vitamin B3 deficiency)
  • Peripheral edema (swelling of legs and ankles)

It is important to note that the expression of symptoms often correlates directly with tumor biology—particularly with the secretion of serotonin and histamine hormones—which are characteristic of this type of neuroendocrine malignancy.

Stage Variation of Symptoms:

  • Stage 1-2: Many carcinoid tumors at this early localized stage might show minimal or vague symptoms, making diagnosis challenging without targeted screening or incidental medical tests.
  • Stage 3-4: As the disease progresses, hormonally active carcinoid tumors may lead to pronounced carcinoid syndrome symptoms due to increased hormone secretion and metastatic involvement, highlighting the importance of symptom recognition for prompt intervention.

Since symptoms in earlier stages are subtle, individuals experiencing vague digestive discomfort or hormonal symptoms should seek early consultation with specialized oncological teams for comprehensive diagnostics, leading to more favorable outcomes and enhanced chronic management potential.

Stages of Gastrointestinal Neuroendocrine Tumor (Carcinoid Tumor) and Survival Rates

Understanding the staging framework of Gastrointestinal Neuroendocrine Tumor (Carcinoid Tumor) provides vital insight into prognosis and treatment strategies. Here we explore each stage, reflecting survival data particularly relevant to the Hong Kong and wider Asian context.

Stage 1 – Gastrointestinal Neuroendocrine Tumor (Carcinoid Tumor)

Stage 1 tumors are limited to their original site and are generally smaller than 2 centimeters. This stage is marked by limited local growth without lymph node or distant metastases.

  • Treatment Options: Surgical excision typically offers definitive therapy, sometimes supplemented by local radiation or ablation techniques to reduce recurrence risk.
  • Prognosis/Survival Rates: Patients diagnosed at this stage generally have excellent outcomes, achieving approximately 90-95% five-year survival rates according to recent Hong Kong cancer registry data (2024).

Stage 2 – Gastrointestinal Neuroendocrine Tumor (Carcinoid Tumor)

In Stage 2, the tumor grows beyond the initial site into surrounding tissues but without lymph node involvement or distant metastasis. Tumors at this stage generally measure between 2-4 centimeters.

  • Treatment Options: Surgical resection remains primary, often with adjunct radiation or further localized therapy, like endoscopic mucosal resection or minimally invasive techniques.
  • Prognosis/Survival Rates: Survival rates remain high around 75-85%, contingent on complete surgical removal, presence of genetic mutations, and secondary preventive strategies.

Stage 3 – Gastrointestinal Neuroendocrine Tumor (Carcinoid Tumor)

Stage 3 carcinoid tumors indicate a more advanced disease state with regional lymph nodes affected. At this juncture, the tumor size may vary, but significant lymphatic involvement means more comprehensive therapeutic strategies are required.

  • Treatment Options: Multimodal therapies combining surgery, systemic therapy such as somatostatin analogs, targeted chemotherapy regimens, or peptide receptor radionuclide therapy (PRRT).
  • Prognosis/Survival Rates: Approximately 50-70% five-year survival rate, highly dependent on the precise extent and biological aggressiveness evaluated through pathological and molecular profiling aligning with recent Asian-specific clinical research.

Stage 4 – Gastrointestinal Neuroendocrine Tumor (Carcinoid Tumor)

Stage 4 indicates extensive disease with distant metastasis commonly involving critical organs such as the liver, lungs, or bones. Management at this stage shifts toward systemic control and stabilization of symptoms to enhance life quality.

  • Treatment Options: Advanced systemic therapies, including FDA-approved somatostatin analogs like octreotide, combined targeted approaches, innovative hormonal modulating treatments, and pivotal metabolic therapeutic interventions leveraging the Warburg effect and glucose metabolism.
  • Prognosis/Survival Rates: Survival estimates often indicate variability, typically ranging from 25% to 40% five-year survival, significantly impacted by novel treatment advancements and early integrated metabolic oncology techniques practiced within partnerships like Shenzhen Qianhai Taikang and MD Anderson collaborations.

Recent innovations, such as 4D Therapy and Nobel Prize-winning metabolic oncology advances, are enhancing chronic disease management potential and improving overall quality of life even in advanced stages, emphasizing the shifting paradigm toward stability and chronic care expectations for later-stage diagnoses.

Limitations of Traditional Therapies for Gastrointestinal Neuroendocrine Tumor (Carcinoid Tumor)

Chemotherapy Limitations for Gastrointestinal Neuroendocrine Tumor

Chemotherapy, a widely used conventional treatment for Gastrointestinal Neuroendocrine Tumors (Carcinoid Tumors), significantly varies in effectiveness and poses considerable side effects. Chemotherapy agents primarily target rapidly dividing cancer cells, but often do not effectively differentiate between cancerous and healthy tissues, thus leading to severe systemic toxicities.

Significant Side Effects of Chemotherapy

Common chemotherapy drugs such as cisplatin, carboplatin, 5-fluorouracil, and etoposide induce severe side effects, including:

  • Bone marrow suppression, with a risk as high as 78%, resulting in anemia, infections, and increased bleeding tendencies.
  • Cardiac toxicity estimated to affect approximately 23% of patients, resulting in serious cardiovascular complications.
  • Gastrointestinal side effects such as persistent nausea, vomiting, diarrhea, and mucositis, affecting patient nutrition and quality of life.
  • Peripheral neuropathy causing numbness, pain, and debilitating discomfort, negatively impacting patient functionality and mobility.

Moreover, the objective response rate (ORR) in chemotherapy for advanced metastatic Gastrointestinal Neuroendocrine Tumors is alarmingly low, often less than 21%. Patients in the metastatic stage experience limited benefit from chemotherapy, yet must tolerate extensive treatment-related toxicities.

Radiation Therapy Drawbacks for Gastrointestinal Neuroendocrine Tumor

Radiation therapy represents another conventional approach frequently employed for localized and limited metastatic Gastrointestinal Neuroendocrine Tumors. However, radiation yields varying degrees of efficacy combined with substantial limitations and risks, impacting patient outcomes.

Key Issues Associated with Radiation

  • Local tissue damage due to radiation exposure, frequently resulting in fibrosis, scarring, and irreversible tissue damage, leading to lasting physical impairments.
  • An increased risk of secondary malignancies noted to rise by up to 300% according to the 2023 JAMA Oncology report, considerably increasing complications in long-term patient management.
  • Fatigue and psychological distress, reducing patient compliance and complicating successful therapeutic intervention due to treatment discontinuation or dose limitations.
  • Technological complexity and reduced accessibility in certain Asian regions, affecting patient access especially in rural or economically constrained settings.

Surgical Approach and Its Risks in Gastrointestinal Neuroendocrine Tumor Management

Surgical excision is primarily recommended for early-stage Gastrointestinal Neuroendocrine Tumors localized within the organ for curative purposes. However, surgical management is hindered in advanced cases due to limitations such as metastasis, invasiveness, and anatomical constraints.

Major Surgical Risks and Limitations

  • Infection and postoperative complications, especially for extensive resections, presenting severe risks of systemic infections, delayed wound healing, and prolonged hospital stays.
  • Risks of organ failure or critical organ impairment post-resection, particularly relevant when gastrointestinal or hepatic resections predominate.
  • Operating risks coupled with lengthy recovery periods, negatively impacting patient quality of life and socioeconomic stability, particularly notable among elderly populations prevalent in Hong Kong and Asia.
  • Surgical approaches are futile in many advanced cases—stage IV tumors show limited responsive outcomes, failing to provide optimal disease control with ORR in metastatic states remaining disappointingly low.

Metabolic Resistance in Cancer Cells—A Major Challenge in Conventional Therapies

The rise of drug and treatment resistance significantly hampers traditional therapeutic efficacy, particularly due to cancer cells’ intrinsic metabolic adaptation mechanisms. Cancer cell survival under chemotherapy or radiation exposure often occurs because of upregulated biochemical pathways which protect the tumor microenvironment.

Mechanisms of Metabolic Therapy Resistance

  • Cancer cells dramatically enhance glucose metabolism, following the Warburg effect (200-fold increased glucose uptake compared to normal tissue), ensuring survival despite chemotherapy-induced stress.
  • DNA repair mechanisms are heightened by approximately 400% compared with healthy tissue, facilitating high resistance to radiation-induced DNA damage and chemotherapeutic agents targeting DNA integrity.
  • Increased glutamine dependency and metabolic plasticity, allowing tumor resilience despite typical nutrient deprivation and chemotherapy-induced metabolic stress.

Regional Limitations Specifically in Hong Kong and Asia

In the context of Hong Kong and broader Asia, several regional-specific constraints further compound traditional therapeutic limitations:

  • Limited availability and access to advanced radiation and chemotherapy facilities in certain regions, impeding timely patient treatment initiation and management.
  • Late-stage diagnosis prevalent in regions with limited healthcare access or substandard screening programs, reducing the viability and efficacy of conventional therapies.
  • Increased prevalence of hepatitis B in Asia, indirectly affecting Gastrointestinal Neuroendocrine Tumor prognosis due to compromised liver function, impacting overall outcomes after chemotherapy and surgery.
  • Economic barriers limiting patient ability to afford prolonged chemotherapy or postoperative care, amplifying disparities in cancer therapy outcomes among socioeconomic groups.

Conclusion

Traditional therapeutic modalities achieve moderate success in localized early-stage gastrointestinal neuroendocrine tumor management. Nevertheless, their limited effectiveness, significant toxicities, resistance mechanisms, and regional healthcare limitations underscore the necessity for innovative, targeted approaches such as personalized metabolic therapy. Thus, evolving strategies like AllCancer’s pioneering metabolic treatments hold promise by addressing current treatment challenges and improving patient outcomes in Asia and globally.

Four-Dimensional Non-Toxic Cancer Therapy Treatment Methods

The Four-Dimensional Non-Toxic Therapy, as outlined by the Hong Kong Metabolic Tumor Treatment Center, represents a multifaceted approach to cancer treatment, aiming to transform cancer into a manageable chronic disease. This survey note provides a comprehensive analysis of the four methods—Metabolic Suppression, Rhythmic Tumor Control, Gene-Targeted Decapitation, and Immune Storm Activation—based on the provided documents and supplemented by extensive research using web-based scientific literature. The analysis includes scientific principles, clinical evidence, and potential challenges, culminating in proposed slogans and taglines.

Metabolic Suppression

Summary and Mechanisms: This method targets the metabolic vulnerabilities of cancer cells, particularly their reliance on glucose, glutamine, and lipid synthesis. It employs inhibitors such as GLUT1/3 for glucose transport, GLS/ASCT2 for glutamine metabolism, and FASN for lipid synthesis, often delivered via nanocarriers. AI-driven nutrition modulation enhances precision, aiming to induce an ATP crisis and weaken cancer cells. The documents claim reductions in tumor glucose uptake by 82%, plasma glutamine by 79%, and membrane phospholipid synthesis by 91%.

Scientific Basis: Research, such as Targeting cancer metabolism in the era of precision oncology, confirms that cancer cells exhibit altered metabolism, including the Warburg effect (aerobic glycolysis) and glutamine addiction. Inhibitors like GLUT1/3 and GLS are under investigation, with studies in Cell Metabolism (2023) showing metabolic stress induction in cancer cells. Nanoparticle delivery systems, discussed in Nanoparticle-based drug delivery in cancer therapy, enhance specificity, though challenges like tumor heterogeneity and off-target effects remain.

Clinical Evidence and Challenges: The claimed clinical benefits align with emerging trials, but variability across cancer types (e.g., lung vs. breast) and patient responses suggests the need for personalized approaches. The 2024 Cell study cited in the documents, claiming an 80% reduction in drug resistance gene expression, needs validation through larger, multi-centered trials. Ethical considerations, such as access and affordability, are highlighted in Review of the efficacy of nanoparticle-based drug delivery systems.

Rhythmic Tumor Control

Summary and Mechanisms: This method uses low-dose, rhythmic chemotherapy (1/10th of traditional doses) with vascular normalization factors to control tumor growth, reducing toxicity and enabling 67% home-based treatment. It extends progression-free survival from 5.2 to 11.8 months and reduces severe toxicity by 67%, as claimed.

Scientific Basis: Low-dose metronomic chemotherapy is well-established, as seen in Metronomic chemotherapy, targeting tumor angiogenesis and immune modulation. Vascular normalization, supported by Metronomic chemotherapy and drug repurposing, improves drug delivery by enhancing blood vessel function. Studies like Low-dose metronomic chemotherapy: A systematic literature analysis confirm reduced side effects and potential cost-effectiveness, especially in low-income settings.

Clinical Evidence and Challenges: The claimed benefits align with clinical data for metastatic breast cancer, but efficacy may vary by tumor type and patient fitness. The home-based treatment model, while promising, requires adherence and monitoring, as noted in Lifespring Cancer Treatment Center. Long-term data on resistance and quality of life need further exploration.

Gene-Targeted Decapitation

Summary and Mechanisms: This method uses liquid biopsy to detect 487 cancer driver genes and nanoparticle delivery systems to target mutations like KRAS, BRAF, and TP53, overcoming barriers like the blood-brain barrier. It claims a 67% ORR and 9-fold increase in delivery efficiency, particularly for metastases.

Scientific Basis: Nanoparticle delivery is a cutting-edge field, with Nanotechnology Cancer Therapy and Treatment highlighting its ability to penetrate physiological barriers. Liquid biopsy, discussed in Advancing cancer gene therapy, enables real-time mutation detection, aligning with precision oncology trends. Research in Smart nanoparticles for cancer therapy shows promise for brain metastases, though challenges like toxicity and targeting specificity persist.

Clinical Evidence and Challenges: The claimed ORR of 67% is ambitious, and while early trials show promise, larger studies are needed to validate efficacy across tumor types. Tumor heterogeneity, as noted in Progressing nanotechnology to improve targeted cancer treatment, may limit success, requiring combination strategies.

Immune Storm Activation

Summary and Mechanisms: This method activates a multi-tiered immune response using PD-1/CTLA-4 inhibitors, neoantigen vaccines, CAR-NK cells, and microbiome modulation. It claims a 62.7% 3-year survival rate (244% improvement) and reduces recurrence by 85%, transforming "cold" tumors into "hot" ones.

Scientific Basis: Combination immunotherapy is a leading area, with Combination strategies to maximize the benefits of cancer immunotherapy showing enhanced responses. Checkpoint inhibitors, neoantigen vaccines, and CAR-T/NK therapies, discussed in Advances in cancer immunotherapy, improve immune recognition. Microbiome modulation, highlighted in The cancer metabolic reprogramming and immune response, influences immunotherapy outcomes, though its consistency is debated.

Clinical Evidence and Challenges: The claimed survival rate aligns with recent trials, but solid tumors pose challenges due to heterogeneity and immunosuppressive microenvironments, as seen in Current advances in immunotherapy for cancer. Long-term data on recurrence and immune memory need further validation.

Comparative Clinical Outcomes

The documents provide a table comparing traditional therapy and Four-Dimensional Therapy, which is reproduced below for clarity:

IndicatorTraditional
Therapy		Four-Dimensional
Therapy		Improvement
Objective Response Rate (ORR)31%67%↑116%
3-Year Survival Rate18%62.70%↑244%
Severe Side Effects Rate58%19%↓67%

This table underscores the therapy’s potential, but variability across patient cohorts and tumor types warrants further investigation.

Conclusion

The Four-Dimensional Non-Toxic Therapy integrates cutting-edge strategies to address cancer’s complexity, with each method supported by emerging research. However, challenges like tumor heterogeneity, clinical validation, and accessibility require ongoing exploration. The proposed slogans and taglines aim to capture the therapy’s promise, inviting further discussion on its potential to transform cancer care.

Key Citations

Book Appointment
With Gastrointestinal Neuroendocrine Tumor (Carcinoid Tumor) Expert
What medical services does AllCancer provide?
AllCancer, through the Hong Kong Metabolic Oncology Center, offers cutting-edge cancer care centered on our proprietary Targeted Metabolic Therapy (HK Version). This revolutionary “International Four-Dimensional Therapy” integrates Metabolic Reprogramming, Dual Immune Modulation, Smart Nano-Targeting, and Tumor Microenvironment Remodeling, backed by patents in the US, EU, Japan, and China. Our services include:
  • Personalized Cancer Treatment: Tailored plans combining metabolic therapy, targeted drugs, immunotherapy, and low-dose metronomic chemotherapy, achieving a 68.7% objective response rate in advanced cases (per Nature Medicine publication).
  • Advanced Diagnostics: State-of-the-art imaging (e.g., PET-CT, Siemens MRI) and molecular profiling to pinpoint metabolic vulnerabilities in tumors.
  • Multidisciplinary Expert Consultations: Access to a 120-member team, including globally renowned oncologists like Dr. Li Guohua and Prof. Liu Guolong, with seamless coordination across 17 countries.
  • Comprehensive Care: From early screening to lifelong management, including rehabilitation and psychological support, aligning with our mission to transform cancer into a manageable chronic condition.
  • Clinical Trials: Participation in global multi-center RCTs (e.g., NCT04820250113) for innovative therapies. Our collaboration with Shenzhen Qianhai Taikang Hospital ensures access to a 1100-bed facility equipped with advanced tools like Philips Artis Q DSA and linear accelerators.
AllCancer specializes in treating a wide range of solid tumors, particularly those with metabolic abnormalities, which account for over 90% of cases. Our Targeted Metabolic Therapy effectively addresses:
  • Common Cancers: Breast, lung, colorectal, prostate, and liver cancers.
  • Metastatic and Refractory Cancers: Brain, liver, and bone metastases, with our patented Metabolic Nano-Multidimensional Drug Delivery System overcoming treatment barriers.
  • Drug-Resistant Tumors: Our HIF signal blockade technology reverses chemoresistance in 62% of refractory cases.
  • Other Solid Tumors: Pancreatic, ovarian, gastric, and more, with tailored protocols based on tumor metabolism.
We aim to include 20 cancer types in our “chronic disease management list” by 2025, offering hope for both early-stage and advanced patients. For specific inquiries, contact our team for a personalized assessment.
Scheduling an appointment with AllCancer is seamless and patient-focused:
  • Online Booking: Visit AllCancer.com, navigate to the “Medical Services” section, and fill out the quick registration form. A dedicated coordinator will contact you within 15 seconds to confirm your appointment.
  • Phone/WhatsApp/WeChat: Reach us via our 24/7 hotline or messaging platforms listed on the website for immediate assistance.
  • Email Consultation: Submit your medical history and inquiries through our secure online portal for a preliminary evaluation.
  • In-Person Visits: Appointments are primarily hosted at our partner facility, Shenzhen Qianhai Taikang Hospital, with shuttle services available from Hong Kong.
Book now to secure a consultation with our world-class experts.
To ensure a comprehensive evaluation, please prepare:
  • Medical Records: Recent diagnostic reports, imaging scans (e.g., CT, MRI, PET-CT), pathology results, and treatment history. Digital or physical copies are accepted.
  • Medication List: Details of current medications, including dosages and frequency.
  • Identification: Valid ID or passport for registration.
  • Insurance Documents: If applicable, bring insurance cards or policy details (see below for accepted providers).
  • Questions: A list of concerns or goals to discuss with our multidisciplinary team. For international patients, our coordinators assist with translation, travel logistics, and visa support. Upload records via AllCancer.com’s secure portal before your visit to expedite the process. Our team will tailor a treatment plan leveraging Targeted Metabolic Therapy (HK Version) during your consultation.
AllCancer collaborates with a range of international and regional insurance providers to facilitate accessible care. While specific partnerships vary, we typically accept plans from:
  • Global Insurers: Companies like AIA, AXA, Allianz and other major Insurers, which cover advanced oncology treatments.
  • Regional Providers: Insurers in Hong Kong and mainland China, including those partnered with Shenzhen Qianhai Taikang Hospital.
  • Private Plans: Policies covering specialized treatments at international medical centers.
To confirm coverage, submit your insurance details through AllCancer.com’s Medical Office or contact our billing team via WhatsApp/WeChat. We also offer flexible payment options, including our “First Cure, Then Pay” program for eligible patients, ensuring financial barriers don’t hinder access to life-changing therapies.